Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis

Multiple Sclerosis

Volumn 14, Issue 9, 2008, Pages 1208-1213

  Thangarajh, M ^a   Gomez Rial, J ^b   Hedstrom A K ^a   Hillert, J ^a   Alvarez Cermeno J C ^b   Masterman, Thomas ^a   Villar, L M ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Biological markers; Cerebrospinal fluid; Immunoglobulin M; Multiple sclerosis; Prognosis; Survival analysis

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M ANTIBODY; INTERFERON BETA SERINE; LIPID SPECIFIC IMMUNOGLOBULIN M; NATALIZUMAB; OLIGOCLONAL BAND; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; LIPID;

ADOLESCENT; ADULT; ADVERSE OUTCOME; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; CEREBROSPINAL FLUID EXAMINATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HEADACHE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PATIENT ASSESSMENT; PROGNOSIS; CEREBROSPINAL FLUID; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PREDICTION AND FORECASTING;

ADOLESCENT; ADULT; ANTIBODY SPECIFICITY; BIOLOGICAL MARKERS; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LIPIDS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OLIGOCLONAL BANDS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; YOUNG ADULT;

EID: 59249107126     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458508095729     Document Type: Article

References (20)

1. Lucchinetti C Brück W Parisi J Scheithauer B Rodriguez M Lassmann H. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707-717.
2. Bielekova B Kadom N Fisher E. MRI as a marker for disease heterogeneity in multiple sclerosis. Neurology 2005; 65: 1071-1076.
3. Noseworthy JH Lucchinetti C Rodriguez M Weinshenker BG. Multiple sclerosis. N Engl J Med 2000; 343: 938-952.
4. Ebers GC. Natural history of multiple sclerosis. J Neurol Neurosurg Psychiatry 2001; 71(Suppl. 2): Ii16-ii19.
5. Bielekova B Martin R. Development of biomarkers in multiple sclerosis. Brain 2004; 127: 1463-1478.
6. Rudick RA French CA Breton D Williams GW. Relative diagnostic value of cerebrospinal fluid kappa chains in MS: Comparison with other immunoglobulin tests. Neurology 1989; 39: 964-968.
7. Rinker JR Trinkaus K Cross AH. Elevated CSF free kappa light chains correlate with disability prognosis in multiple sclerosis. Neurology 2006; 67: 1288-1290.
8. Izquierdo G Angulo S Garcia-Moreno JM. Intrathecal IgG synthesis: Marker of progression in multiple sclerosis patients. Acta Neurol Scand 2002; 105: 158-163.
9. Avasarala JR Cross AH Trotter JL. Oligoclonal band number as a marker for prognosis in multiple sclerosis. Arch Neurol 2001; 58: 2044-2045.
10. Villar LM Sádaba MC Roldán E. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest 2005; 115: 187-194.
11. McDonald WI Compston A Edan G. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
12. Roxburgh RH Seaman SR Masterman T. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005; 64: 1144-1151.
13. Villar LM García-Barragán N Espiño M. Influence of oligoclonal IgM specificity in multiple sclerosis disease course. Mult Scler 2008; 14: 183-187.
14. Lublin FD Reingold SC. Defining the clinical course of multiple sclerosis: Results of an interRational survey: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907-911.
15. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
16. Sharief MK Thompson EJ. The predictive value of intrathecal immunoglobulin synthesis and magnetic resonance imaging in acute isolated syndromes for subsequent development of multiple sclerosis. Ann Neurol 1991; 29: 147-151.
17. Villar LM Masjuan J González-Porqué P. Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology 2002; 59: 555-559.
18. Perini P Ranzato F Calabrese M Battistin L Gallo P. Intrathecal IgM production at clinical onset correlates with a more severe disease course in multiple sclerosis. J Neurol Neurosurg Psychiatry 2006; 77: 953-955.
19. Berland R Wortis HH. Origins and functions of B-1 cells with notes on the role of CD5. Annu Rev Immunol 2002; 20: 253-300.
20. Lennon VA Wingerchuk DM Kryzer TJ. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet 2004; 364: 2106-2112.